Ranch Capital Advisors’s Myriad Genetics MYGN Stock Holding History

Ranch Capital Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-800	Closed	-$26K	–	404
2021 Q3	$26K	Buy	800 +200	+33%	+$6.64K	0.02%	347
2021 Q2	$18K	Sell	600 -50	-8%	-$1.45K	0.01%	516
2021 Q1	$19K	Sell	650 -50	-7%	-$1.42K	0.01%	480
2020 Q4	$13K	Buy	+700	New	+$11.3K	0.01%	579

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Ranch Capital Advisors's MYGN Position: Q4 2021 in Review

Ranch Capital Advisors sold out of Myriad Genetics (MYGN) in Q4 2021, closing a stake of 800 shares — an estimated $26K sold.

Ranch Capital Advisors first reported a position in MYGN in Q4 2020 and held it in 4 quarters. The position peaked at $26K in Q3 2021. 197 funds tracked by Wall St. Rank hold MYGN as of Q4 2021.

Ranch Capital Advisors reported no remaining Myriad Genetics position as of Q4 2021 after selling out during the quarter.
Ranch Capital Advisors sold 800 Myriad Genetics shares in Q4 2021, an estimated $26K.
Ranch Capital Advisors first reported a position in Myriad Genetics in Q4 2020 and held it in 4 quarters.
Ranch Capital Advisors's Myriad Genetics position peaked at $26K in Q3 2021.
197 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2021.

Based on Ranch Capital Advisors's 13F filing for Q4 2021, filed 8 Feb 2022.